Skip to main content
SpringerLink
Log in

NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia

  • Letter To The Editors
  • Published:
Psychopharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Andersen PH, Gronvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB (1992) NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol 219:45–52

    Google Scholar 

  • Chouinard G, Rosse-Chouinard A, Annable L, Jones BD (1980) The extrapyramidal symptoms rating scale. Can J Neurol Sci 7:2233–2239

    Google Scholar 

  • Gerlach J, Lublin H, Peacock L (1995) Dopamine D1 receptor antagonists in rodents, in primates and in humans. In: Fog R, Gerlach J, Hemmingsen R (eds) Schizophrenia. Alfred Benzon Symposium 38. Munksgaard, Copenhagen, pp 300–309

    Google Scholar 

  • Guy W (1976) NCDEU assessment manual for psychopharmacology revised. DHEW Pub. No. (ADM) 76–338:217–222

  • Kay SR, Opler LA, Lindenmayer JP (1988) Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23:99–110

    Google Scholar 

  • Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. Acta Psychiatr Scand 76 [Suppl 334] 81–94

    Google Scholar 

  • Nielsen EB, Andersen PH, Farde L, Karlsson P, Gronvald FC, Skrumsager BK (1992) Preclinical pharmacology and clinical effects in humans of dopamine D-1 receptor antagonism. Soc Neurosci Abstr 18.202

Download references

Author information

Authors and Affiliations

  1. Dept. P and The Research Institut of Biological Psychiatry, St. Hans Psychiatric Hospital, DK-4000, Roskilde, Denmark

    J. Karle, H. Lublin & J. Gerlach

  2. Department of Psychiatry, Frederiksberg Hospital, DK-2000, Frederiksberg, Denmark

    L. Clemmesen & L. Hansen

  3. Vordingborg Psychiatric Hospital, DK-4760, Vordingborg, Denmark

    M. Andersen & J. Andersen

  4. Aalborg Psychiatric Hospital, DK-9000, Aalborg, Denmark

    C. Fensbo

  5. Novo Nordisk, Clinical Research CNS, DK-2880, Bagsvaerd, Denmark

    M. Sloth-Nielsen & B. K. Skrumsager

Authors
  1. J. Karle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Lublin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Gerlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Clemmesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Fensbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Sloth-Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B. K. Skrumsager
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karle, J., Lublin, H., Gerlach, J. et al. NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology 121, 328–329 (1995). https://doi.org/10.1007/BF02246071

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02246071

Keywords

Search

Navigation